{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:02:36Z","timestamp":1793757756812,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":1418,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1186\/s13613-022-01095-5","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T02:02:56Z","timestamp":1672452176000},"page":"121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Auto-antibodies against type I IFNs in\u2009>\u200910% of critically ill COVID-19 patients: a prospective multicentre study"],"prefix":"10.1016","volume":"12","author":[{"given":"Romain","family":"Arrestier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bastard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaut","family":"Belmondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Voiriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Urbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles-Edouard","family":"Luyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Bizien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauriane","family":"Segaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Ben Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Bella\u00efche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta\u00ef","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakaria","family":"Ait-Hamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Clere-Jehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Gaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mayaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafid","family":"Ait-Oufella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Moncomble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lodie","family":"Parfait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Dorgham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Gorochov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Mekontso-Dessap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Canoui-Poitrine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Laurent","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4833-4320","authenticated-orcid":false,"given":"Nicolas","family":"de Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1186\/s13613-022-01095-5_bb0010","unstructured":"WHO Coronavirus (COVID-19) Dashboard [Internet]. https:\/\/covid19.who.int. Accessed 21 Feb 2022."},{"key":"10.1186\/s13613-022-01095-5_bb0015","unstructured":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020\u201321. The Lancet [Internet]. https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(21)02796-3\/fulltext. Accessed 20 Apr 2022."},{"key":"10.1186\/s13613-022-01095-5_bb0020","first-page":"430","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature Nature Publishing Group"},{"key":"10.1186\/s13613-022-01095-5_bb0025","doi-asserted-by":"crossref","first-page":"eabd4570","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1186\/s13613-022-01095-5_bb0030","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1186\/s13613-022-01095-5_bb0035","doi-asserted-by":"crossref","first-page":"eabl4348","DOI":"10.1126\/sciimmunol.abl4348","article-title":"X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19","volume":"6","author":"Asano","year":"2021","journal-title":"Sci Immunol."},{"key":"10.1186\/s13613-022-01095-5_bb0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.it.2015.01.004","article-title":"Interferons and viruses: an evolutionary arms race of molecular interactions","volume":"36","author":"Hoffmann","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0045","doi-asserted-by":"crossref","first-page":"eabl4340","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths","volume":"6","author":"Bastard","year":"2021","journal-title":"Sci Immunol."},{"key":"10.1186\/s13613-022-01095-5_bb0050","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s10875-021-01036-0","article-title":"Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid","volume":"41","author":"Troya","year":"2021","journal-title":"Spain J Clin Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-021-01203-3","article-title":"Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French Hospital","author":"Chauvineau-Grenier","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1327","article-title":"Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients","volume":"10","author":"Goncalves","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0065","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s10875-021-01136-x","article-title":"Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in Barcelona","volume":"41","author":"Solanich","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0070","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/imcb.12495","article-title":"Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19","volume":"99","author":"Abers","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"10.1186\/s13613-022-01095-5_bb0075","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1186\/s13613-022-01095-5_bb0080","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00134-021-06392-4","article-title":"Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients","volume":"47","author":"with the Amsterdam UMC COVID-19 Biobank Investigators","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-022-01095-5_bb0085","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s10875-021-01168-3","article-title":"Interferon-\u03b12 auto-antibodies in convalescent plasma therapy for COVID-19","volume":"42","author":"Raadsen","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0090","doi-asserted-by":"crossref","first-page":"eabh2624","DOI":"10.1126\/scitranslmed.abh2624","article-title":"Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19","volume":"13","author":"van der Wijst","year":"2021","journal-title":"Sci Transl Med."},{"key":"10.1186\/s13613-022-01095-5_bb0095","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10875-021-01060-0","article-title":"Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma","volume":"41","author":"Vazquez","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","article-title":"Diverse functional autoantibodies in patients with COVID-19","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"10.1186\/s13613-022-01095-5_bb0105","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1016\/j.cell.2021.07.023","article-title":"Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19","volume":"184","author":"Ziegler","year":"2021","journal-title":"Cell"},{"key":"10.1186\/s13613-022-01095-5_bb0110","doi-asserted-by":"crossref","DOI":"10.1007\/s10875-021-00994-9","article-title":"Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia","author":"de Prost","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"key":"10.1186\/s13613-022-01095-5_bb0120","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","author":"Marshall","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1186\/s13613-022-01095-5_bb0125","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-022-01095-5_bb0130","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new Simplified Acute Physiology Score (SAPS II) based on a European\/North American multicenter study","volume":"270","author":"Le Gall","year":"1993","journal-title":"JAMA"},{"key":"10.1186\/s13613-022-01095-5_bb0135","article-title":"The Berlin definition","author":"Acute Respiratory Distress Syndrome","year":"2012","journal-title":"JAMA"},{"key":"10.1186\/s13613-022-01095-5_bb0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00134-020-06294-x","article-title":"Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study","volume":"47","author":"COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1186\/s13613-022-01095-5_bb0145","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210554","article-title":"Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1","volume":"218","author":"Bastard","year":"2021","journal-title":"J Exp Med"},{"key":"10.1186\/s13613-022-01095-5_bb0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41590-021-01091-0","article-title":"Innate immunity: the first line of defense against SARS-CoV-2","volume":"23","author":"Diamond","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0155","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"10.1186\/s13613-022-01095-5_bb0160","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1126\/science.adf2350","article-title":"A viral arsenal","volume":"378","author":"Leslie","year":"2022","journal-title":"Science"},{"key":"10.1186\/s13613-022-01095-5_bb0165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.coi.2022.01.003","article-title":"Type I interferons and SARS-CoV-2: from cells to organisms","volume":"74","author":"Bastard","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"10.1186\/s13613-022-01095-5_bb0170","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","article-title":"Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1186\/s13613-022-01095-5_bb0175","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/art.39607","article-title":"Distinct functions of anti-interferon autoantibodies in systemic lupus erythematosus: a comprehensive analysis of anticytokine autoantibodies in common rheumatologic diseases","volume":"68","author":"Gupta","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1186\/s13613-022-01095-5_bb0180","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3390\/v14071529","article-title":"SARS-CoV-2 genomic characteristics and clinical impact of SARS-CoV-2 viral diversity in critically ill COVID-19 patients: a prospective multicenter cohort study","volume":"14","author":"Fourati","year":"2022","journal-title":"Viruses"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01095-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-022-01095-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025006892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025006892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-022-01095-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:40:23Z","timestamp":1776670823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025006892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2110582025006892"],"URL":"https:\/\/doi.org\/10.1186\/s13613-022-01095-5","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Auto-antibodies against type I IFNs in\u2009>\u200910% of critically ill COVID-19 patients: a prospective multicentre study","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-022-01095-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Author(s) 2022. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"121"}}